Market Overview

Bayer Cleared in Generic Yaz Delay But Will Settle Blood Clot Lawsuits


The Yaz Resource Center is the Web's largest source for information on Yaz research, side effects and legal news. Visit

Dallas, TX (PRWEB) October 25, 2012

The Federal Trade Commission announced this month that Bayer will not face any retribution over the 2008 settlement of patent litigation with Teva Pharmaceuticals, which had been suspected as a ploy to delay the release of generic Yasmin, according to an NBC News report on October 2, 2012.

However, the birth control drugs Yaz and Yasmin have been linked to increased risks of blood clots, most recently when the British Medical Journal last October published a study from the University of Copenhagen highlighting Yaz side effects.

Based on a Bloomberg News report on July 31, 2012, Bayer has now reserved up to $610 million to settle the thousands of claims that have been filed by patients for blood clot-related conditions.

On October 27, 2011, the FDA released a study entitled "Combined Hormonal Contraceptives and the Risk of Cardiovascular Disease Endpoints" showing drugs like Yaz could increase the risk of blood clots, DVT and pulmonary embolism by as much as 74%.

A federal Multi-District Litigation court was established in Illinois to handle Yaz lawsuits filed by those injured. The formal case is known as Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois). The court estimates that more than 10,000 patients have filed a claim.

Bloomberg News reported on July 31st that Bayer has resolved as many as 1900 Yaz settlements so far at an average of around $212,000 per case. They have also reserved up to $610 million to settle more of the cases, but indicated they are only settling those related to blood clots.

The news of Yaz lawsuit settlements is positive for those injured who have yet to file a claim. However, time is limited and only certain cases may qualify.

Anyone who suffered a blood clot, DVT, Pulmonary Embolism or stroke after taking Yaz or Yasmin is urged to contact the Yaz Resource Center or speak with a lawyer about their legal options.

The Yaz Resource Center cautions that victims should seek a lawyer with experience in defective drug litigation, and only recommends lawyers and law firms who have already settled Yaz lawsuits.

For more information on research, side effects and litigation news related to the drug Yaz, or to speak with a lawyer, visit

For the original version on PRWeb visit:

View Comments and Join the Discussion!